Aktienanalyse zu United Therapeutics Corp (UTHR)UTHRUnited Therapeutics Corp

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

United Therapeutics Corp is currently a hold. The stock is priced at $533.12, which is below several analyst price targets, including $728 from BTIG and $708 from RBC Capital. However, the RSI is at 45.857, indicating that the stock is neither overbought nor oversold, suggesting caution. The recent settlement with Liquidia has removed significant legal uncertainties, but the stock has seen a 2.92% decline over the last five days, indicating potential short-term volatility. The main risk is the Goldman Sachs target of $321, representing a 34% downside from current levels, which investors should consider before making a decision.

13 analysts cover UTHR: 2 rate it Buy, 6 Hold and 5 Sell. The average price target is 534.50.